Study says people over 40 with HIV would benefit from also taking this medication
The British HIV Association recommends that everyone over 40 living with HIV should be offered statins for the primary prevention of cardiovascular disease, regardless of their cholesterol levels.
The recommendations are based on the findings of the REPRIEVE study, which showed that participants assigned statins had a significantly lower risk of developing major cardiovascular problems.
Diabetes and obesity rising in young Americans, study finds
Rising rates of diabetes and obesity among young adults in the United States are putting them at higher risk for heart disease.
Black and Hispanic people, particularly Mexican Americans, are at a higher risk for these health issues and could bear the brunt of the consequences.
Structural racial inequities in American society contribute to the disparities in health outcomes among young adults.
Doctors Reveal The Damage That 1 Day Of Thanksgiving Food Can Do
Part of what makes Thanksgiving so special is that many of the foods on the table are only enjoyed during this particular meal - and you get to have them all at the same time!
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.